Kodiak Sciences Inc. (KOD)

Market Cap	172.28M
Revenue (ttm)	n/a
Net Income (ttm)	-260.49M
Shares Out	52.52M
EPS (ttm)	-4.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	250,894
Open	3.200
Previous Close	3.185
Day's Range	3.170 - 3.370
52-Week Range	1.370 - 9.800
Beta	2.13
Analysts	Sell
Price Target	3.25 (-0.91%)
Earnings Date	May 13, 2024

About KOD

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative dia...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 4, 2018
• Employees: 111
• Stock Exchange: NASDAQ
• Ticker Symbol: KOD

Analyst Forecast

According to 7 analysts, the average rating for KOD stock is "Sell." The 12-month stock price forecast is $3.25, which is a decrease of -0.91% from the latest price.

Price Target

$3.25

(-0.91% downside)

Analyst Consensus: Sell